Novel Therapeutic Target for Pulmonary Fibrosis/Scleroderma

OCR Number: 
OCR 57674445
  • Fibrotic lung diseases represents a major unmet medical need, as effective treatment options are currently not available.
  • Mice that overexpress TGF-β have identified several novel targets (including β1 integrin) for therapeutic interventions in fibrotic lung diseases.
  • The blockade of β1 integrin significantly inhibits fibrosis (collagen formation).
  • Semaphorin 7A inhibition (Figure B) is also effective as a therapeutic treatment for fibrotic disease.
Kang, H. R., Lee, C. G., Homer, R. J., & Elias, J. A. (2007). Semaphorin 7A plays a critical role in TGF-β1–induced pulmonary fibrosis. The Journal of experimental medicine, 204(5), 1083-1093. [Pub Med]
Licensing Contact: